POINT Biopharma Global Inc. (PNT) stock surged +0.16%, trading at $12.50 on NASDAQ, up from the previous close of $12.48. The stock opened at $12.50, fluctuating between $12.49 and $12.51 in the recent session.
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.
Employees | 129 |
Beta | 0 |
Sales or Revenue | $226.58M |
5Y Sales Change% | 0% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
POINT Biopharma Global Inc. (NASDAQ: PNT) stock price is $12.50 in the last trading session. During the trading session, PNT stock reached the peak price of $12.51 while $12.49 was the lowest point it dropped to. The percentage change in PNT stock occurred in the recent session was 0.16% while the dollar amount for the price change in PNT stock was $0.02.
The NASDAQ listed PNT is part of Biotechnology industry that operates in the broader Healthcare sector. POINT Biopharma Global Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Todd Hockemeyer B.E.
Executive Vice President of US Manufacturing Operations
Ms. Donna Husack B.A.
Vice President of HR
Ms. Jessica D. Jensen M.P.H., MPH
Executive Vice President of Clinical Devel.
Dr. Myra Rosario Herle Ph.D., R.Ph.
Executive Vice President of Regulatory Affairs
Mr. Chris Horvath
Executive Vice President of Commercial
Mr. Allan Charles Silber
Executive Chairman
Mr. Ari Shomair
Vice President of Corporation Affairs & Chief of Staff
Dr. Joe A. McCann Ph.D.
Chief Executive Officer & Director
Ms. Justyna Kelly M.Sc.
Chief Operating Officer
Dr. Matthew P. Vincent J.D., Ph.D.
Senior Vice President of Bus. Devel.
Ms. Melita Ann Sequeira B.Sc.
Senior Vice President of People & Culture
Dr. Neil E. Fleshner FRCSC, M.D., M.PH
Chief Medical Officer & Director
Mr. Bill Demers B.B.A., F.C.A., FCPA
Chief Financial Officer & Corporation Sec.
PNT's closing price is 90.26% higher than its 52-week low of $6.57 where as its distance from 52-week high of $14.35 is -12.89%.
Number of PNT employees currently stands at 129.
Official Website of PNT is: https://www.pointbiopharma.com
PNT could be contacted at phone 647 812 2417 and can also be accessed through its website. PNT operates from 4850 West 78th Street, Indianapolis, IN 46268, United States.
PNT stock volume for the day was 3.29M shares. The average number of PNT shares traded daily for last 3 months was 3.85M.
The market value of PNT currently stands at $1.33B with its latest stock price at $12.50 and 106.57M of its shares outstanding.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com